Autologous Cell Therapy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

Description

Persistence Market Research has recently released a comprehensive report on the worldwide market for autologous cell therapy. The report provides a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, offering detailed insights into the market structure.

Key Insights:

Autologous Cell Therapy Market Size (2024E):US$5.3 Bn
Projected Market Value (2031F):US$12.1 Bn
Global Market Growth Rate (CAGR 2024 to 2031): 12.6%

Autologous Cell Therapy Market - Report Scope:

Autologous cell therapy involves using a patient's own cells for treatment, which can be applied to various medical conditions including cancer, autoimmune disorders, and degenerative diseases. This market includes a range of therapies such as stem cell treatments, CAR-T cell therapies, and regenerative medicine. The market caters to hospitals, specialized clinics, and research institutions, offering tailored therapies based on individual patient needs. Market growth is driven by advancements in cell therapy technologies, increasing prevalence of chronic diseases, and expanding research into novel treatment approaches.

Market Growth Drivers:

The global autologous cell therapy market is propelled by several key factors, including rising awareness about personalized medicine and the increasing adoption of advanced cell therapies for treating complex diseases. The growing incidence of cancers, autoimmune disorders, and degenerative conditions fuels demand for effective and targeted treatments. Technological advancements, such as improved cell processing techniques and the development of more sophisticated cell manipulation methods, enhance the efficacy and safety of autologous therapies. Additionally, increasing investments in research and development and favorable regulatory frameworks are further stimulating market growth.

Market Restraints:

Despite promising growth prospects, the autologous cell therapy market faces challenges related to high treatment costs, complex manufacturing processes, and regulatory hurdles. The development and production of autologous therapies require significant investment and specialized infrastructure, which can limit accessibility and affordability. Regulatory complexities and the need for rigorous clinical trials to ensure safety and efficacy also pose barriers to market expansion. Furthermore, limited reimbursement options for autologous therapies and potential ethical concerns related to stem cell research can impact market growth.

Market Opportunities:

The autologous cell therapy market presents significant growth opportunities driven by technological innovations, expanding applications, and evolving healthcare delivery models. The integration of advanced technologies, such as artificial intelligence and robotics in cell processing, is enhancing treatment precision and efficiency. The increasing focus on regenerative medicine and personalized treatments for various conditions opens new avenues for market players. Strategic partnerships, investment in cutting-edge research, and the development of cost-effective therapies are essential to capitalize on emerging opportunities and drive market growth.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the autologous cell therapy market globally?
Which types of autologous cell therapies are seeing the most adoption across different healthcare settings?
How are technological advancements reshaping the competitive landscape of the autologous cell therapy market?
Who are the key players contributing to the autologous cell therapy market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global autologous cell therapy market?

Competitive Intelligence and Business Strategy:

Leading players in the global autologous cell therapy market, including Novartis AG, Gilead Sciences, Inc., and Kite Pharma, Inc., focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced cell therapies, such as CAR-T and stem cell-based treatments, catering to diverse therapeutic needs. Collaborations with research institutions, healthcare providers, and regulatory agencies facilitate market access and promote technology adoption. Emphasis on clinical research, evidence-based practice, and patient-centered approaches is crucial to sustaining market leadership in the rapidly evolving autologous cell therapy landscape.

Key Companies Profiled:

BrainStorm Cell Therapeutics
Holostem Terapie Avanzate S.R.L
Pharmicell Co. Inc
Opexa Therapeutics
Lonza
Bristol Myers Squibb
Tego Science
Corning Incorporated
Bio Elpida
Novartis
Autolus therapeutics
Vericel Corporation
Catalent, Inc
Sartorius AG
Caladrius Biosciences Inc
U.S. Stem Cell Inc

Autologous Cell Therapy Industry Segmentation

By Therapy

Autologous Cellular Immunotherapies
Autologous Stem Cell Therapy

By Application

Cancer
Neurodegenerative disorders
Cardiovascular disorders
Autoimmune disorders
Orthopedics
Wound healing

By Source

Bone Marrow
Epidermis
Mesenchymal stem cells
Haematopoietic stem cells
Chondrocytes

By End-use

Hospitals & Clinics
Ambulatory Centers
Academics & Research

By Geographical Regions

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa

Product Code: PMRREP34713

1. Executive Summary

1.1. Global Autologous Cell Therapy Market Snapshot, 2024-2031
1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Therapy Adoption Analysis
3.2. Technology Assessment
3.3. Regulatory Landscape
3.4. Value Chain Analysis
- 3.4.1. List of Distribution Channel/Marketplaces
  - 3.4.1.1. Retail
  - 3.4.1.2. Audiology
  - 3.4.1.3. E-Commerce
- 3.4.2. List of End User (Industry)
3.5. Key Deals and Mergers
3.6. PESTLE Analysis
3.7. Porter's Five Force Analysis

4. Price Trend Analysis, 2019-2031

4.1. Key Highlights
4.2. Key Factors Impacting Therapy Prices
4.3. Pricing Analysis, By Therapy
4.4. Regional Prices and Therapy Preferences

5. Global Autologous Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

5.1. Key Highlights
- 5.1.1. Market Volume (Units) Projections
- 5.1.2. Market Size (US$ Bn) and Y-o-Y Growth
- 5.1.3. Absolute $ Opportunity
5.2. Market Size (US$ Bn) Analysis and Forecast
- 5.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
- 5.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2031
5.3. Global Autologous Cell Therapy Market Outlook: Therapy
- 5.3.1. Introduction / Key Findings
- 5.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Therapy, 2019-2023
- 5.3.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapy, 2024-2031
  - 5.3.3.1. Autologous Cellular Immunotherapies
  - 5.3.3.2. Autologous Stem Cell Therapy
5.4. Market Attractiveness Analysis: Therapy
5.5. Global Autologous Cell Therapy Market Outlook: Application
- 5.5.1. Introduction / Key Findings
- 5.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2023
- 5.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
  - 5.5.3.1. Cancer
  - 5.5.3.2. Neurodegenerative disorders
  - 5.5.3.3. Cardiovascular disorders
  - 5.5.3.4. Autoimmune disorders
  - 5.5.3.5. Orthopedics
  - 5.5.3.6. Wound healing
  - 5.5.3.7. Others
5.6. Market Attractiveness Analysis: Application
5.7. Global Autologous Cell Therapy Market Outlook: Source
- 5.7.1. Introduction / Key Findings
- 5.7.2. Historical Market Size (US$ Bn) Analysis, By Source, 2019-2023
- 5.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Source, 2024-2031
  - 5.7.3.1. Bone Marrow
  - 5.7.3.2. Epidermis
  - 5.7.3.3. Mesenchymal stem cells
  - 5.7.3.4. Haematopoietic stem cells
  - 5.7.3.5. Chondrocytes
  - 5.7.3.6. Others
5.8. Market Attractiveness Analysis: Source Global Autologous Cell Therapy Market Outlook: End Use
- 5.8.1. Introduction / Key Findings
- 5.8.2. Historical Market Size (US$ Bn) Analysis, By End Use, 2019-2023
- 5.8.3. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2024-2031
  - 5.8.3.1. Hospitals & Clinics
  - 5.8.3.2. Ambulatory Centers
  - 5.8.3.3. Academics & Research
  - 5.8.3.4. Others
5.9. Market Attractiveness Analysis: Source

6. Global Autologous Cell Therapy Market Outlook: Region

6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019-2023
6.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2024-2031
- 6.3.1. North America
- 6.3.2. Europe
- 6.3.3. East Asia
- 6.3.4. South Asia and Oceania
- 6.3.5. Latin America
- 6.3.6. Middle East & Africa
6.4. Market Attractiveness Analysis: Region

7. North America Autologous Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2023
- 7.3.1. By Country
- 7.3.2. By Therapy
- 7.3.3. By Application
- 7.3.4. By Source
- 7.3.5. By End Use
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 7.4.1. U.S.
- 7.4.2. Canada
7.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapy, 2024-2031
- 7.5.1. Autologous Cellular Immunotherapies
- 7.5.2. Autologous Stem Cell Therapy
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
- 7.6.1. Cancer
- 7.6.2. Neurodegenerative disorders
- 7.6.3. Cardiovascular disorders
- 7.6.4. Autoimmune disorders
- 7.6.5. Orthopedics
- 7.6.6. Wound healing
- 7.6.7. Others
7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Source, 2024-2031
- 7.7.1. Bone Marrow
- 7.7.2. Epidermis
- 7.7.3. Mesenchymal stem cells
- 7.7.4. Haematopoietic stem cells
- 7.7.5. Chondrocytes
- 7.7.6. Others
7.8. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2024-2031
- 7.8.1. Hospitals & Clinics
- 7.8.2. Ambulatory Centers
- 7.8.3. Academics & Research
- 7.8.4. Others
7.9. Market Attractiveness Analysis

8. Europe Autologous Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2023
- 8.3.1. By Country
- 8.3.2. By Therapy
- 8.3.3. By Application
- 8.3.4. By Source
- 8.3.5. By End Use
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. U.K.
- 8.4.4. Italy
- 8.4.5. Spain
- 8.4.6. Russia
- 8.4.7. Turkey
- 8.4.8. Rest of Europe
8.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapy, 2024-2031
- 8.5.1. Autologous Cellular Immunotherapies
- 8.5.2. Autologous Stem Cell Therapy
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
- 8.6.1. Cancer
- 8.6.2. Neurodegenerative disorders
- 8.6.3. Cardiovascular disorders
- 8.6.4. Autoimmune disorders
- 8.6.5. Orthopedics
- 8.6.6. Wound healing
- 8.6.7. Others
8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Source, 2024-2031
- 8.7.1. Bone Marrow
- 8.7.2. Epidermis
- 8.7.3. Mesenchymal stem cells
- 8.7.4. Haematopoietic stem cells
- 8.7.5. Chondrocytes
- 8.7.6. Others
8.8. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2024-2031
- 8.8.1. Hospitals & Clinics
- 8.8.2. Ambulatory Centers
- 8.8.3. Academics & Research
- 8.8.4. Others
8.9. Market Attractiveness Analysis

9. East Asia Autologous Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2023
- 9.3.1. By Country
- 9.3.2. By Therapy
- 9.3.3. By Application
- 9.3.4. By Source
- 9.3.5. By End Use
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 9.4.1. China
- 9.4.2. Japan
- 9.4.3. South Korea
9.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapy, 2024-2031
- 9.5.1. Autologous Cellular Immunotherapies
- 9.5.2. Autologous Stem Cell Therapy
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
- 9.6.1. Cancer
- 9.6.2. Neurodegenerative disorders
- 9.6.3. Cardiovascular disorders
- 9.6.4. Autoimmune disorders
- 9.6.5. Orthopedics
- 9.6.6. Wound healing
- 9.6.7. Others
9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Source, 2024-2031
- 9.7.1. Bone Marrow
- 9.7.2. Epidermis
- 9.7.3. Mesenchymal stem cells
- 9.7.4. Haematopoietic stem cells
- 9.7.5. Chondrocytes
- 9.7.6. Others
9.8. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2024-2031
- 9.8.1. Hospitals & Clinics
- 9.8.2. Ambulatory Centers
- 9.8.3. Academics & Research
- 9.8.4. Others
9.9. Market Attractiveness Analysis

10. South Asia & Oceania Autologous Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2023
- 10.3.1. By Country
- 10.3.2. By Therapy
- 10.3.3. By Application
- 10.3.4. By Source
- 10.3.5. By End Use
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 10.4.1. India
- 10.4.2. Southeast Asia
- 10.4.3. ANZ
- 10.4.4. Rest of South Asia & Oceania
10.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapy, 2024-2031
- 10.5.1. Autologous Cellular Immunotherapies
- 10.5.2. Autologous Stem Cell Therapy
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
- 10.6.1. Cancer
- 10.6.2. Neurodegenerative disorders
- 10.6.3. Cardiovascular disorders
- 10.6.4. Autoimmune disorders
- 10.6.5. Orthopedics
- 10.6.6. Wound healing
- 10.6.7. Others
10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Source, 2024-2031
- 10.7.1. Bone Marrow
- 10.7.2. Epidermis
- 10.7.3. Mesenchymal stem cells
- 10.7.4. Haematopoietic stem cells
- 10.7.5. Chondrocytes
- 10.7.6. Others
10.8. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2024-2031
- 10.8.1. Hospitals & Clinics
- 10.8.2. Ambulatory Centers
- 10.8.3. Academics & Research
- 10.8.4. Others
10.9. Market Attractiveness Analysis

11. Latin America Autologous Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

11.1. Key Highlights
11.2. Pricing Analysis
11.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2023
- 11.3.1. By Country
- 11.3.2. By Therapy
- 11.3.3. By Application
- 11.3.4. By Source
- 11.3.5. By End Use
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 11.4.1. Brazil
- 11.4.2. Mexico
- 11.4.3. Rest of Latin America
11.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapy, 2024-2031
- 11.5.1. Autologous Cellular Immunotherapies
- 11.5.2. Autologous Stem Cell Therapy
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
- 11.6.1. Cancer
- 11.6.2. Neurodegenerative disorders
- 11.6.3. Cardiovascular disorders
- 11.6.4. Autoimmune disorders
- 11.6.5. Orthopedics
- 11.6.6. Wound healing
- 11.6.7. Others
11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Source, 2024-2031
- 11.7.1. Bone Marrow
- 11.7.2. Epidermis
- 11.7.3. Mesenchymal stem cells
- 11.7.4. Haematopoietic stem cells
- 11.7.5. Chondrocytes
- 11.7.6. Others
11.8. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2024-2031
- 11.8.1. Hospitals & Clinics
- 11.8.2. Ambulatory Centers
- 11.8.3. Academics & Research
- 11.8.4. Others
11.9. Market Attractiveness Analysis

12. Middle East & Africa Autologous Cell Therapy Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

12.1. Key Highlights
12.2. Pricing Analysis
12.3. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Market, 2019-2023
- 12.3.1. By Country
- 12.3.2. By Therapy
- 12.3.3. By Application
- 12.3.4. By Source
- 12.3.5. By End Use
12.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 12.4.1. GCC Countries
- 12.4.2. Egypt
- 12.4.3. South Africa
- 12.4.4. Northern Africa
- 12.4.5. Rest of Middle East & Africa
12.5. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Therapy, 2024-2031
- 12.5.1. Autologous Cellular Immunotherapies
- 12.5.2. Autologous Stem Cell Therapy
12.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
- 12.6.1. Cancer
- 12.6.2. Neurodegenerative disorders
- 12.6.3. Cardiovascular disorders
- 12.6.4. Autoimmune disorders
- 12.6.5. Orthopedics
- 12.6.6. Wound healing
- 12.6.7. Others
12.7. Current Market Size (US$ Bn) Analysis and Forecast, By Source, 2024-2031
- 12.7.1. Bone Marrow
- 12.7.2. Epidermis
- 12.7.3. Mesenchymal stem cells
- 12.7.4. Haematopoietic stem cells
- 12.7.5. Chondrocytes
- 12.7.6. Others
12.8. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2024-2031
- 12.8.1. Hospitals & Clinics
- 12.8.2. Ambulatory Centers
- 12.8.3. Academics & Research
- 12.8.4. Others
12.9. Market Attractiveness Analysis

13. Competition Landscape

13.1. Market Share Analysis, 2024
13.2. Market Structure
- 13.2.1. Competition Intensity Mapping By Market
- 13.2.2. Competition Dashboard
13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 13.3.1. BrainStorm Cell Therapeutics
  - 13.3.1.1. Overview
  - 13.3.1.2. Segments and Therapys
  - 13.3.1.3. Key Financials
  - 13.3.1.4. Market Developments
  - 13.3.1.5. Market Strategy
- 13.3.2. Holostem Terapie Avanzate S.R.L
- 13.3.3. Pharmicell Co. Inc
- 13.3.4. Opexa Therapeutics
- 13.3.5. Lonza
- 13.3.6. Bristol Myers Squibb
- 13.3.7. Tego Science
- 13.3.8. Corning Incorporated
- 13.3.9. Bio Elpida
- 13.3.10. Novartis
- 13.3.11. Autolus therapeutics
- 13.3.12. Vericel Corporation
- 13.3.13. Catalent, Inc
- 13.3.14. Sartorius AG

14. Appendix

14.1. Research Methodology
14.2. Research Assumptions
14.3. Acronyms and Abbreviations